GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Petros Pharmaceuticals Inc (NAS:PTPI) » Definitions » Total Inventories

Petros Pharmaceuticals (Petros Pharmaceuticals) Total Inventories : $1.56 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Petros Pharmaceuticals Total Inventories?

Petros Pharmaceuticals's total inventories for the quarter that ended in Mar. 2024 was $1.56 Mil. Petros Pharmaceuticals's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $1.58 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Petros Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-1.05.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Petros Pharmaceuticals's Days Inventory for the three months ended in Mar. 2024 was 435.22.

Inventory Turnover measures how fast the company turns over its inventory within a year. Petros Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.21.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Petros Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 1.14.


Petros Pharmaceuticals Total Inventories Historical Data

The historical data trend for Petros Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Petros Pharmaceuticals Total Inventories Chart

Petros Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
2.20 0.76 0.52 1.82 1.61

Petros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.04 2.18 2.50 1.61 1.56

Petros Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Petros Pharmaceuticals  (NAS:PTPI) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Petros Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

Net-Net Working Capital Per Share (Q: Mar. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(11.081+0.75 * 1.957+0.5 * 1.557-19.619
-0.907-0)/6.88186
=-1.05

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Petros Pharmaceuticals's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=1.5835/0.332*365 / 4
=435.22

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Petros Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=0.332 / 1.5835
=0.21

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Petros Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=1.5835 / 1.389
=1.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Petros Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Petros Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Petros Pharmaceuticals (Petros Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.
Executives
Wayne Remell Walker director 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Greg Bradley director 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
John D Shulman director, 10 percent owner
Jcp Iii Sm Aiv, L.p. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, L.p. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, Ltd. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Metp Holdings Llc 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Bruce Bernstein director 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Keith Lavan officer: Chief Financial Officer 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Fady Boctor officer: Pres. & Chief Comm. Officer 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Andrew Gesek officer: President, Timm Medical 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Metuchen Therapeutics, Llc 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Mitchell Arnold officer: Prin. Acct. Off/Prin. Fin. Off 200 ROUTE 9 NORTH, SUITE 500, MANALAPAN NJ 07726